EZM2302

A PRMT4 inhibitor (IC50 = 6 nM); decreases asymmetric methylation of PABP1 (IC50 = 0.038 µM) and increases levels of demethylated SmB (EC50 = 0.018 µM) in RPMI-8226 multiple myeloma cells; inhibits proliferation in a panel of 36 hematopoietic cancer cell lines (IC50s = <100 µM for 9 out of 15 multiple myeloma cell lines); reduces tumor growth and decreases asymmetric PABP1 methylation in tumor tissue in an RPMI-8226 mouse xenograft model at 75, 150, and 300 mg/kg twice per day; reduces acute mechanical allodynia and thermal hyperalgesia in a mouse model of CCI-induced neuropathic pain at 10 µg